RayKnowChina Research Map
Shortlist

RecruitingCoronary heart diseaseN/A

Registered title, quoted from ClinicalTrials.gov

Intravascular Ultrasound-Guided PCI in Patients With Chronic Kidney Disease

An open trial on coronary heart disease, registered on ClinicalTrials.gov. Led by First Affiliated Hospital of Xi'an Jiaotong University; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06567938, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 3

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (3 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. CKD patients with eGFR<60 mL/min/1.73 m\^2

    Inclusion criterion 1

    Hemoglobin <60 g/L

    Exclusion criterion 19

  3. Pregnant or childbearing women

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06567938, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • CKD patients with eGFR<60 mL/min/1.73 m\^2
  • De novo coronary lesion suitable for second-generation metallic drug-eluting stent placement and IVUS imaging
  • Signed written informed consent

Exclusion Criteria:

  • Onset of STEMI within 24 hours or emergent angiography
  • Pregnant or childbearing women
  • Co-morbidity with an estimated life expectancy of < 1 year
  • LVEF ≤ 30%
  • Cardiogenic shock or hemodynamic instability
  • Severe hepatic dysfunction, defined as ALT or AST more than 5 times the ULN
  • PCI within the previous 12 months
  • Target lesion of stent thrombosis or in-stent restenosis
  • Any planned non-cardiac surgery within 12 months
  • Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk
  • Current enrolment in other clinical trials
  • Contraindication to anti-platelet agents
  • History of intracranial or gastrointestinal bleeding requiring transfusion or surgical intervention for control (excluding hemorrhoid)
  • Chronic total occlusion lesion with unsuccessful guidewire crossing
  • Current intake of nephrotoxic medications (e.g., nonsteroidal anti-inflammatory drugs except acetylsalicylic acid, phenylbutazone, aminoglycosides, amphotericin B, polymyxin, platinum complexes)
  • Immune-related kidney disease or on hormone therapy (e.g. lupus nephritis, IgA nephropathy)
  • Planned exposure to contrast within 72 h after the procedure, intravascular administration of contrast within the previous 5 days
  • Intake of anticoagulants
  • Hemoglobin <60 g/L
  • Severe valvular disease or valvular disease likely to require surgery or percutaneous valve replacement during the trial
  • Patients allergic to metals or contrast

Quoted from ClinicalTrials.gov, NCT06567938, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06567938, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06567938